Lin Nung-Sheng, Lin Yen-Yue, Kao Yung-Hsi, Chuu Chih-Pin, Wu Kuo-An, Chan Jenq-Shyong, Hsiao Po-Jen
Department of Emergency, Taoyuan Armed Forces General Hospital, Taoyuan 325, Taiwan.
Department of Emergency, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.
Healthcare (Basel). 2022 Mar 10;10(3):507. doi: 10.3390/healthcare10030507.
Ventricular fibrillation (VF) is a life-threatening cardiac arrhythmia that can lead to loss of cardiac function and sudden cardiac death. The most common cause of VF is ischemic cardiomyopathy, especially in the context of an acute coronary event. Prompt treatment with resuscitation and defibrillation can be lifesaving. Refractory VF, or pulseless ventricular tachycardia (pVT), refers to cases that do not respond to traditional advanced cardiac life-support (ACLS) measures, and it has a low survival rate. Some new life-saving interventions and novel techniques have been proposed as viable treatment options for patients presenting with refractory VF/pVT out-of-hospital cardiac arrest; these include extracorporeal membrane oxygenation (ECMO), esmolol, stellate ganglion block (SGB), and double sequential defibrillation (DSD). Recently, DSD has been discussed and used more frequently, but its survival rate is still not promising. We report a case of refractory VF caused by acute myocardial infarction that was treated with ACLS, DSD, ECMO, and cardiac catheterization in sequence, with a successful outcome.
心室颤动(VF)是一种危及生命的心律失常,可导致心功能丧失和心源性猝死。VF最常见的病因是缺血性心肌病,尤其是在急性冠状动脉事件的背景下。及时进行复苏和除颤治疗可挽救生命。难治性VF或无脉性室性心动过速(pVT)是指对传统的高级心脏生命支持(ACLS)措施无反应的病例,其生存率较低。对于院外心脏骤停的难治性VF/pVT患者,已提出一些新的挽救生命的干预措施和新技术作为可行的治疗选择;这些措施包括体外膜肺氧合(ECMO)、艾司洛尔、星状神经节阻滞(SGB)和双序列除颤(DSD)。最近,DSD已被更多地讨论和使用,但其生存率仍然不容乐观。我们报告一例由急性心肌梗死引起的难治性VF病例,该病例先后接受了ACLS、DSD、ECMO和心脏导管插入术治疗,结果成功。